

# Cervarix Shows 100% Efficacy Through 5.5 Years

BY MIRIAM E. TUCKER  
Senior Writer

ATLANTA — The investigational cervical cancer vaccine Cervarix remained 100% effective through 5.5 years in preventing cervical intraepithelial neoplasia lesions associated with human papillomavirus strains 16 and 18, Dr. Gary Dubin reported at a meeting of the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices.

The finding comes from the second interim analysis of the long-term follow-up phase of GlaxoSmithKline's primary efficacy trial for its bivalent HPV 16/18 vaccine, in which 1,113 women aged 15-25 years were randomized to receive the vaccine or placebo.

Safety, immunogenicity, and efficacy were initially evaluated for up to 27 months (Lancet 2004;365:1757-65), and

**No vaccine recipient had HPV 16/18-related cytology (atypical squamous cells of undetermined significance), nor cervical intraepithelial neoplasia lesions.**

the first interim analysis of the long-term follow-up phase was performed in October 2005 (Lancet 2006; 367:1247-55). The final analysis will come at the end of 2007, said Dr. Dubin, who is vice president and director of GSK's Clinical

Development and Medical Affairs, Prophylactic Vaccines, North America.

At 63-64 months following receipt of the first vaccine dose, ELISA titers to HPV strains 16 and 18 were both 11 times higher in the vaccine recipients than in the placebo group. From the end of the initial (27-month) study phase through a mean follow-up of 5.5 years, 1 incident HPV 16/18 infection occurred in a vaccine recipient, compared with 43 infections among the controls, giving a vaccine efficacy of 98.1%. The infection in the one vaccine recipient did not persist at 6 and 12 months, however, whereas 19 controls had persistent infection at 6 months and 9 infections persisted at 12 months.

As had been found at the two previous analyses, no vaccine recipient had HPV 16/18-related cytology classified as atypical squamous cells of undetermined significance (ASCUS) or greater, or cervical intraepithelial neoplasia (CIN) lesions. In contrast, 24 controls had HPV 16/18-related ASCUS or higher and 5 had HPV 16/18 CIN lesions at 5.5 years. Cervarix is formulated with a special adjuvant that has been shown to induce a higher and more persistent immune response, compared with vaccines formulated with aluminum salts only (Vaccine 2006;24:5937-49).

The vaccine also showed evidence of cross-protection against HPV types 45 and 31, the third and fourth most common strains associated with cervical cancer worldwide. Efficacy against incident infection with HPV 45 was 88%, and against HPV-31, 54%. Worldwide, 2.9% of all cervical cancers are attributed to HPV 31,

6.7% to HPV 45, 17.2% to HPV 18, and 53.5% to HPV 16 (Int. J. Cancer 2004; 111:278-85).

In a separate immunobridging study involving 666 women aged 15-55 years, HPV 16/18 antibody titers were of the same order of magnitude as those associated with protection in the efficacy study. There is a need for an HPV vaccine in women over 25 years of age, because new infections with HPV cancer types are estimated to occur in 5.3% of women aged 25-55 years.

Moreover, although new infections do decrease with age, the risk of persistence actually increases with age. "Our target is that women over 25 years are not denied access to the GSK cervical cancer vaccine," Dr. Dubin said.

A double-blind, randomized, controlled phase III efficacy trial involving 18,665 women aged 15-25 years in 14 countries is underway. The women received either GSK's HPV vaccine or the hepatitis A vaccine as a control on a 0-, 1-, 6-month vac-

ination schedule. The required number of events—HPV 16/18-associated CIN2 or higher lesions—were accrued in November 2006. Those data will be presented "in the near future." A study of the vaccine's efficacy in 5,700 women over 25 years of age is also ongoing, while trials looking at coadministration with other routine adolescent vaccines, safety and immunogenicity in HIV-positive women, and other local registration trials in several countries are planned. ■

## CALLING ALL ADOLESCENTS AND ADULTS



**A CALL TO ARMS**  
AGAINST PERTUSSIS

Pertussis protection for both adolescents and adults 11 through 64 years of age

**Adacel**<sup>®</sup>

Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed

Arming More People Against Pertussis



### Safety Information

ADACEL vaccine is indicated for active booster immunization for the prevention of tetanus, diphtheria, and pertussis as a single dose in persons 11 through 64 years of age.

As with any vaccine, ADACEL vaccine may not protect 100% of vaccinated individuals. There are risks associated with all vaccines. The most common injection site adverse events include pain, erythema, and swelling. The most common systemic adverse events include headache, body ache, tiredness, and fever. ADACEL vaccine is contraindicated in persons with known systemic hypersensitivity to any component of the vaccine or a life-threatening reaction after previous administration of the vaccine or a vaccine containing the same substances. Because of uncertainty as to which component of the vaccine may be responsible, no further vaccination with the diphtheria, tetanus, or pertussis components found in ADACEL vaccine should be carried out. Because any intramuscular injection can cause injection site hematoma, ADACEL vaccine should not be given to persons with any bleeding disorder, such as hemophilia or thrombocytopenia, or to persons on anticoagulant therapy unless the potential benefits clearly outweigh the risk of administration. If the decision is made to administer ADACEL vaccine to such persons, it should be given with caution, with steps taken to avoid the risk of hematoma formation following injection.

Before administering ADACEL vaccine, please see brief summary of full Prescribing Information on following page.

ADACEL vaccine is manufactured by Sanofi Pasteur Limited and distributed by Sanofi Pasteur Inc.

To order ADACEL vaccine, log onto [www.vaccineshoppe.com](http://www.vaccineshoppe.com) or call 1-800-VACCINE (1-800-822-2463)

Learn about pertussis disease and prevention at [www.ADACELVACCINE.com](http://www.ADACELVACCINE.com)

### References:

1. Centers for Disease Control and Prevention (CDC). Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. *MMWR*. 2006;55(RR-17):21-22. 2. CDC. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines: recommendations of the ACIP. *MMWR*. 2006;55(RR-3):22.

\* Advisory Committee on Immunization Practices. † Tetanus, diphtheria, and acellular pertussis. ‡ 19-64 years of age. § 11-18 years of age.

sanofi pasteur. Discovery Drive, Swiftwater, Pennsylvania 18370. [www.sanofipasteur.us](http://www.sanofipasteur.us)  
MKT12997 © 2007 Sanofi Pasteur Inc. 2/07 Printed in USA

**sanofi pasteur**  
The vaccines business of sanofi-aventis Group